Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ: BIIB )

229.57 -3.28 (-1.41%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 5, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 861,300
Open 232.00
Bid (Size) 228.50 (4)
Ask (Size) 230.55 (1)
Prev. Close 232.85
Today's Range 229.16 - 232.48
52wk Range 220.86 - 319.76
Shares Outstanding 144,000,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Doing Your Holiday Shopping? These Stocks Might Make Great Gifts
No matter which holiday you're planning gifts for, Christmas, Hanukkah, or some other occasion, there may be one great gift idea you haven't thought of yet. 
Via MarketBeat
Topics Bonds
Exposures Debt Markets
Comparative Study: Biogen And Industry Competitors In Biotechnology Industry
Via Benzinga

Performance

YTD
-15.79%
-15.79%
1 Month
-7.67%
-7.67%
3 Month
-13.79%
-13.79%
6 Month
-23.42%
-23.42%
1 Year
-21.58%
-21.58%

More News

Read More
Alzheimer's Disease Vaccines: Promising Developments, Renewed Enthusiasm From Biogen, Eli Lilly And Others
Via Benzinga
Here's How Much $1000 Invested In Biogen 20 Years Ago Would Be Worth Today
Via Benzinga
Industry Comparison: Evaluating Biogen Against Competitors In Biotechnology Industry
Via Benzinga
Expert Ratings for Biogen
Via Benzinga
Quest For Alzheimer's Cure: Big Biotech Breakthroughs, But The Race Is Just Beginning
Via Investor's Business Daily
Stock Market Rally Pauses As Yields Rebound; Datadog, Affirm Among Earnings Winners: Weekly Review
Via Investor's Business Daily
The Alzheimer's Drug Market Is Heating Up. Should You Buy the Leading Contenders' Stocks?
Via The Motley Fool
Looking Into Biogen's Recent Short Interest
Via Benzinga
Here's How Much You Would Have Made Owning Biogen Stock In The Last 15 Years
Via Benzinga
Assessing Biogen's Performance Against Competitors In Biotechnology Industry
Via Benzinga
These Analysts Revise Their Forecasts On Biogen After Q3 Results
Via Benzinga
Thoughts For Thursday: Staying On Top - Barely
Via Talk Markets
Biogen (BIIB) Q3 2023 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Biogen Revises Annual Forecast As Reata M&A And Alzheimer's Drug Expenses Hit Bottomline, Stock Slides
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Compared To Estimates, Biogen Inc. Q3 Earnings: A Look At Key Metrics
Via Talk Markets
US Stocks Set To Open Flat After Hot 7-Day Rally: Traders Sharpen Focus On Powell's Speech, Disney Earnings
Via Benzinga
Topics Economy
Exposures Interest Rates
Biogen Tops Earnings Forecasts, But Cuts Profit Outlook As Leqembi Expenses Mount
Via Investor's Business Daily
3 Biotech Moonshots to Bet on the Future of Health
Via InvestorPlace
Topics Intellectual Property
Exposures Intellectual Property
Biogen Appoints Monish Patolawala to its Board of Directors
From Biogen Inc.
Via GlobeNewswire
Biogen Pulls Prothena Into A Steep Dive On Mixed Results For Alzheimer's Treatment
Via Investor's Business Daily
Eisai Presents New LEQEMBI® (lecanemab-irmb) Investigational Subcutaneous Formulation Interim Study Results and Clinical Improvement Data in Earlier Stages of Early Alzheimer’s Disease From Additional Analyses of Clarity AD at The Clinical Trials On
From Biogen Inc.
Via GlobeNewswire
Biogen Says New Data Shows Promise For Potential New Generation Of Treatments In Early Alzheimer's Disease
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.